Infant Bacterial Therapeutics AB (publ)
Infant Bacterial Therapeutics AB (publ) operates as a clinical stage pharmaceutical company develops and markets drugs to prevent serious neonatal diseases affecting premature infants in Sweden. The company's lead drug candidate is IBP-9414, which is in Phase III clinical studies to prevent necrotizing enterocolitis, as well as to improve feeding tolerance in premature infants. It is also develop… Read more
Infant Bacterial Therapeutics AB (publ) (IBT-B) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.420x
Based on the latest financial reports, Infant Bacterial Therapeutics AB (publ) (IBT-B) has a cash flow conversion efficiency ratio of -0.420x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-52.25 Million) by net assets (Skr124.36 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Infant Bacterial Therapeutics AB (publ) - Cash Flow Conversion Efficiency Trend (2014–2024)
This chart illustrates how Infant Bacterial Therapeutics AB (publ)'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Infant Bacterial Therapeutics AB (publ) Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Infant Bacterial Therapeutics AB (publ) ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
HMS Bergbau AG
XETRA:HMU
|
-0.399x |
|
Burcelik Bursa Celik Dokum Sanayi AS
IS:BURCE
|
-0.387x |
|
Zeotech Ltd
AU:ZEO
|
-0.230x |
|
Blau Farmacêutica S.A
SA:BLAU3
|
0.059x |
|
IZEA Inc
NASDAQ:IZEA
|
0.024x |
|
Yeo Teknoloji Enerji ve Endustri AS
IS:YEOTK
|
-0.363x |
|
Thai Nguyen International Hospital JSC
VN:TNH
|
0.051x |
|
BUUU Group Limited Class A Ordinary Share
NASDAQ:BUUU
|
N/A |
Annual Cash Flow Conversion Efficiency for Infant Bacterial Therapeutics AB (publ) (2014–2024)
The table below shows the annual cash flow conversion efficiency of Infant Bacterial Therapeutics AB (publ) from 2014 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | Skr170.26 Million | Skr-113.13 Million | -0.664x | -100.32% |
| 2023-12-31 | Skr305.15 Million | Skr-101.22 Million | -0.332x | -28.24% |
| 2022-12-31 | Skr331.71 Million | Skr-85.80 Million | -0.259x | -83.79% |
| 2021-12-31 | Skr395.25 Million | Skr-55.62 Million | -0.141x | -6.08% |
| 2020-12-31 | Skr440.15 Million | Skr-58.39 Million | -0.133x | -31.98% |
| 2019-12-31 | Skr510.40 Million | Skr-51.30 Million | -0.101x | -18.03% |
| 2018-12-31 | Skr556.72 Million | Skr-47.41 Million | -0.085x | +58.75% |
| 2017-12-31 | Skr168.37 Million | Skr-34.76 Million | -0.206x | +45.34% |
| 2016-12-31 | Skr105.23 Million | Skr-39.75 Million | -0.378x | -65.99% |
| 2015-12-31 | Skr74.81 Million | Skr-17.02 Million | -0.228x | +33.45% |
| 2014-12-31 | Skr11.03 Million | Skr-3.77 Million | -0.342x | -- |